NCT03070392 2026-03-17Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal MelanomaImmunocore LtdPhase 2 Completed378 enrolled 15 charts 1 FDA
NCT06581406 2026-02-18A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal MelanomaReplimune Inc.Phase 2/3 Recruiting280 enrolled